Lv5
1150 积分 2022-10-26 加入
Site-Selective Anti-PD-L1 Antibody–MMAE Conjugate for Enhanced NSCLC Therapy
1个月前
已完结
Nonclinical & clinical interface - extrapolation of nonclinical data to support Phase I clinical studies
1个月前
已完结
Exploring the next generation of antibody–drug conjugates
2个月前
已完结
Unlocking biological barriers: nonclinical safety considerations for RNA-based complex biologics
2个月前
已完结
Unlocking biological barriers: nonclinical safety considerations for RNA-based complex biologics
2个月前
已完结
Systematic Evaluation of Maleimide Spacer Impact on Drug-Linker Deconjugation in Antibody-Drug Conjugates Ex Vivo and In Vivo
2个月前
已完结
Unveiling the molecular and immunological drivers of antibody–drug conjugates in cancer treatment
3个月前
已完结
An Industry Perspective on Key Considerations for the ICH S13 Guidance: Nonclinical Safety Evaluations of Oligonucleotide-Based Therapeutics
3个月前
已完结
Targeting DNA damage response pathways in cancer
4个月前
已完结
First-line concomitant EGFR-TKI + chemotherapy versus EGFR-TKI alone for advanced EGFR -mutated NSCLC: a meta-analysis of randomized phase III trials
4个月前
已完结
皖公网安备34019202002308
